What Is Retatrutide? Triple-Agonist Mechanism and Current Research
An evidence-based overview of retatrutide (LY3437943), an investigational peptide designed to activate GIP, GLP-1, and glucagon receptors, including its molecular design, published clinical research, safety findings, and current research status.
Educational and research information only. AETHELON BIO products are intended for research use only and are not intended for human consumption. Content on this page is not medical advice.
Overview
Retatrutide, also known by the development code LY3437943, is an investigational peptide designed to activate three hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucagon receptor. Because a single molecule has agonist activity at all three receptors, retatrutide is commonly described as a “triple agonist.” This distinguishes its design from compounds that target only GLP-1 or combinations of GLP-1 and GIP signaling. Retatrutide has been evaluated in clinical trials, including Phase 2 and Phase 3 studies. It remains investigational and is not an FDA-approved drug as of September 2026. This article reviews the scientific literature and does not provide medical advice or directions for use.
Molecular Design and Receptor Activity
Retatrutide is a single peptide molecule engineered to exhibit agonist activity at the GIP, GLP-1, and glucagon receptors. The published Phase 2 report describes retatrutide as a peptide conjugated to a fatty diacid moiety. Its pharmacokinetic profile includes an approximate six-day half-life in the clinical development program. The scientific interest surrounding the molecule comes partly from combining three receptor activities within a single molecular design. GLP-1 and GIP participate in nutrient-responsive signaling, while glucagon signaling has important roles in energy metabolism and substrate utilization. Researchers have investigated whether combining these pathways produces biological effects distinct from targeting fewer receptors.
Why Three Receptors?
GLP-1, GIP, and glucagon are involved in overlapping but distinct aspects of metabolic physiology. GLP-1 and GIP are incretin hormones associated with nutrient-responsive signaling. Glucagon has established roles in glucose and energy metabolism. Retatrutide was designed to investigate the combined effects of agonism across all three receptor systems. The authors of the Phase 2 obesity trial discussed the possibility that adding glucagon-receptor activity to GLP-1/GIP agonism could influence energy intake, substrate utilization, and energy expenditure. These proposed interactions remain areas of active scientific investigation rather than proof of a specific mechanism explaining every observed clinical effect.
Published Phase 2 Research
A randomized, double-blind, placebo-controlled Phase 2 trial published in the New England Journal of Medicine in 2023 enrolled 338 adults with obesity or overweight plus at least one weight-related condition. Participants were assigned to placebo or different retatrutide dose and dose-escalation groups. At 48 weeks, the reported least-squares mean body-weight changes ranged from −8.7% in the 1 mg group to −24.2% in the 12 mg group, compared with −2.1% with placebo. These findings came from a controlled clinical trial and should be interpreted within that specific study population, protocol, duration, and investigational setting. They do not establish that independently sold retatrutide products are equivalent to the investigational product studied in Lilly-sponsored clinical trials.
Safety Findings in Phase 2
Safety was also evaluated in the Phase 2 study. The most frequently reported adverse events with retatrutide were gastrointestinal, including nausea, diarrhea, vomiting, and constipation. These events occurred more frequently in retatrutide groups than with placebo and were generally more frequent at higher doses. The study also reported dose-dependent increases in heart rate that peaked around 24 weeks and subsequently declined. Treatment discontinuation because of adverse events occurred in 6% to 16% of participants receiving retatrutide, depending on the study group, compared with none of the placebo participants. These observations are part of the investigational safety dataset and should not be interpreted as establishing the complete safety profile of retatrutide.
Phase 3 Research
Retatrutide subsequently advanced into the Phase 3 TRIUMPH clinical-development program. ClinicalTrials.gov lists TRIUMPH-1 as a Phase 3 randomized, double-blind, placebo-controlled study sponsored by Eli Lilly. The study enrolled 2,335 participants and evaluated retatrutide in adults with obesity or overweight without type 2 diabetes, including specified study populations involving knee osteoarthritis and obstructive sleep apnea. ClinicalTrials.gov records the study as completed in April 2026. Eli Lilly has also announced topline results from additional Phase 3 TRIUMPH studies. Company-announced topline results are useful for understanding development status, but they should be distinguished from complete peer-reviewed publications because full datasets and analyses may not yet have undergone the same scientific review.
Current Regulatory and Research Status
As of September 2026, Retatrutide remains investigational and is not FDA-approved. Eli Lilly has stated that it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027. A planned future submission is not equivalent to FDA approval. The FDA has also specifically warned about unapproved Retatrutide products marketed outside the authorized clinical-development process, including products presented as being for research purposes when circumstances indicated consumer human use. Therefore, data generated with Lilly's investigational clinical-trial material should not be assumed to establish the identity, purity, quality, safety, or equivalence of independently manufactured products bearing the same compound name.
Research Limitations and Interpretation
Retatrutide research should be interpreted with several limitations in mind. Clinical-trial results apply to the populations, investigational product, protocols, endpoints, and durations studied. Phase 2 findings do not by themselves establish long-term safety or outcomes outside the controlled clinical-trial setting. Topline Phase 3 announcements should be distinguished from complete peer-reviewed publications. Research involving a defined investigational product also does not establish the quality or equivalence of products obtained from unrelated suppliers. Retatrutide remains an active area of clinical investigation. Future peer-reviewed Phase 3 publications and regulatory review will provide additional evidence regarding its efficacy, safety, and benefit-risk profile. Educational and research information only. This article is not medical advice and does not provide instructions for human use.
References
- [1]Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — New England Journal of Medicine (2023)Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Milicevic, Mark L. Hartman, for the Retatrutide Phase 2 Obesity Trial Investigators
- [2]A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) — ClinicalTrials.gov (2026)Eli Lilly and Company
- [3]FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (2026)U.S. Food and Drug Administration